Pharmatwob Ltd.

Curegenics Ltd.

Pninit Litman

Nurit Livnah

Hanoch Senderowitz

Tamar Yechezkel

Ilana Cohen

Yosef Salitra

Boris Perlmutter

Sarit Zaksh

Onsat Ohne

A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline.

Fixed dose combination therapy of Parkinson's disease

The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.

Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics

Growing community of inventors

Ness Ziona, Israel

Pninit Litman